



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 12 Aug 2019 (#26)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- **NIH Terminology: Know the Nine Application Types.** NIH uses application types in the application number to identify various stages in the lifecycle of a grant.
- **ORCID iD: Required for Some, Encouraged for All.** If you will be supported by an NIH training (T), fellowship (F), education, or career development (K) award in fiscal year (FY) 2020, you must create an [ORCID iD](#) and associate it with your eRA Commons Personal Profile.
- **Five Helpful NIH and NIAID Webpages to Bookmark**
 1. **NIH Guide:** Updated daily, the [NIH Guide to Grants and Contracts](#) is your go-to source for grant funding opportunities and policy announcements.
 2. **Electronic application and system news:** NIH updates the [NIH eSubmission Items of Interest](#) page several times a year to reflect key developments and news on electronic application and submission topics.
 3. **Catch the latest breakthroughs:** The journal search at [PubMed](#) can help you stay on top of developments in your area of science. [NIH Research Matters](#) highlights successful funded research each week.
 4. **Find funding priorities and trends:** Compare your research ideas with the [NIH-Wide Strategic Plan](#), updated every four years. Be sure to [Understand NIAID Research Priorities](#) using resources such as our thrice-yearly [Concepts: Potential Opportunities](#).
 5. **Social media sites.** NIH offers a huge index of [Social Media & Outreach](#) accounts, many of which provide daily updates. Similarly, there are plenty of ways to [Connect With NIAID](#) on social media.
- **You might be surprised to learn that NIH doesn't have a generic set of forms posted on the website that you can use to submit to any NIH grant opportunity.** Each [funding opportunity announcement \(FOA\)](#) includes the specific set of forms needed to apply to that program, so you need to find an FOA in order to access the application forms. Walk through the process of finding and accessing application forms with this [grant application submission tips for success video](#). Form-by-form, field-by-field instructions for completing your application may be found on the [How to Apply – Application Guide](#) page under the green header for Application Form Instructions. Use these

instructions in conjunction with the guidance in the funding opportunity announcement (including the Related Notices section of the announcement) to develop your application. The [annotated form sets](#) are another handy tool to help you navigate the forms.

- **Am I required to include a cover letter in my application?** Possibly. Certain situations, like submitting a late application or proposing a study that will generate large-scale genomic data, necessitate a cover letter. Find a full list of cases in which a cover letter is mandated or optional at [Write a Cover Letter](#).
- **How can I tell whether my grant is eligible to be renewed?** Eligibility is determined by the funding opportunity announcement (FOA) to which you'll apply, rather than the active grant. In *Section II. Award Information* of the FOA, under "Application Types Allowed," check to see if renewal is listed. Remember, you are checking the FOA for your next application, which is not necessarily the same FOA you used for your current grant award.

1. National Heart, Lung and Blood Institute Single-Site Investigator-Initiated Clinical Trials (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-328](#)

Type: R61/R33

Application Due Date: **New and Revision Applications:** October 11, 2019, February 11, 2020, June 10, 2020, October 14, 2020, February 11, 2021, June 10, 2021, October 14, 2021, February 11, 2022, June 10, 2022. **New, Resubmission, and Revision AIDS Applications:** January 14, 2020, May 11, 2020, September 9, 2020, January 14, 2021, May 11, 2021, September 8, 2021, January 14, 2022, May 11, 2022, September 8, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see [NOT-OD-15-015](#)). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the [NHLBI website](#). This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the requested project award period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 1 year for the R61 phase and up to 4 years for the R33 phase.

2. National Heart, Lung, and Blood Institute Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-329](#)

Type: Collaborative UG3/UH3

Application Due Date: **New and Revision Applications:** October 11, 2019, February 11, 2020, June 10, 2020, October 14, 2020, February 11, 2021, June 10, 2021, October 14, 2021, February 11, 2022, June 10, 2022 **Resubmission Applications:** November 12, 2019, March 11, 2020, July 10, 2020, November 17, 2020, March 11, 2021, July 13, 2021, November 15, 2021, March 11, 2022, July 11, 2022 **New, Resubmission, and Revision AIDS Applications:** January 14, 2020, May 11, 2020, September 9, 2020, January 14, 2021, May 11, 2021, September 8, 2021, January 14, 2022, May 11, 2022, September 8, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see [NOT-OD-15-015](#)). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the [NHLBI website](#). This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a Collaborating Data Coordinating Center (DCC) ([PAR-19-330](#)). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating DCC application must be submitted on the same application due date for consideration by NHLBI.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined budgets of the CCC and DCC will be used to determine whether the [policy regarding direct costs of \\$500,000](#) or more in any year will be applied. The scope of the proposed project should determine the requested project award period. The project period for the UG3 phase will be up to 1 year. The project period for the UH3 phase is expected to be 4 years. With strong justification, up to 6 years for the UH3 may be requested.

3. The Biological Mechanisms of Metformin Effects on Aging and Longevity (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-20-044](#)

Type: R01

Application Due Date: January 21, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA invites applications on novel studies of the molecular mechanisms underlying metformin's effects on aging and longevity. The goal of this FOA is to support applications that will lead to an in-depth understanding of the molecular mechanisms that determine the effects of metformin, either beneficial or detrimental, in relation to aging and longevity. Research supported by this FOA should lead to new insights on and better understanding of metformin's effects on aging and aging-related diseases. **Projects**

Non-Responsive to this FOA

- Proposed studies solely focused on diabetes or cancer (without aging context)
- Applications not focused on the molecular mechanisms

Budget: NIA intends to commit \$2 million in FY 2020 to fund 4 - 6 awards. Applications budgets should not exceed \$250,000 per year in direct costs. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105